WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 40'5801 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 39'6781 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 64'721  64'457  64'191  63'920  63'640  59'608  56'961  54'071 
Births 763  766  769  773  776  753  744  749 
Surviving infants 761  764  767  770  773  749  739  741 
Pop. less than 5 years 3'842  3'874  3'894  3'915  3'933  3'698  3'786  3'660 
Pop. less than 15 years 11'763  11'773  11'760  11'739  11'709  11'195  11'326  11'964 
Female 15-49 years 13'819  13'852  13'912  13'974  14'033  14'442  14'118  12'863 

Number of reported cases

(Click for retrospective incidence data for France)
Diphtheria
ChartChart
  14 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  79  157  267  272  10'000  1'244 
Mumps
ChartChart
  17'400 
Pertussis
ChartChart
  56  47  84  165  100 
Polio*
ChartChart
  10 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  10  26  33  208 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for France)
Vaccine year result method % card seen                                                
BCG          83  74 
DTP1          99  99  99  99 
DTP3          97  99  99  99  97  94 
DTP4          91 
IPV1         
HepB_BD         
HepB3          88  82  74  78  26 
Hib3          96  98  98  98  86 
JapEnc         
MCV1          91  90  89  90  84  71 
MCV2          79 
MenA         
PCV1          95  95 
PCV2          92  95 
PCV3          91  89  89  89 
Pol3          97  99  99  99  98  95 
Rota1         
RotaC         
RCV1          91  90  89  90 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for France)
BCG
  83  74  80 
DTP1
ChartChart
  99  99  99  99  99  99  97  92 
DTP3
ChartChart
  97  98  98  99  99  97  94  79 
HepB3
ChartChart
  88  86  83  74  78  26 
HepB_BD
 
Hib3
ChartChart
  96  97  98  98  98  86 
MCV1
ChartChart
  90  91  91  89  90  84  71 
MCV2
ChartChart
  79  78  77  67  72 
PCV3
ChartChart
  91  90  89  89  89 
Pol3
ChartChart
  97  98  98  99  99  98  95  80 
RCV1
ChartChart
  90  91  91  89  90  84  71 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 101  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes children born in Guyanna and Mayotte (B), infant at risk (M1-M2)
DTaP 6 years; Yes
DTaPHibHepIPV 2, 4, 11 months; Yes
HepA_Adult 1, 6 months; No risk groups
HepB_Adult 1, 6, 24 months; Professionnal at risk (health professionnels, fireman, secourists…)
HPV 11-13 years (x2 doses); Yes Girls above 14 years: 3 doses
Influenza_Adult Yes elderly, pregnant women, health care workers, adults with chronic disease and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MenC_conj 5, 12 months; Yes
MMR 12, 18 months; Yes
Pneumo_conj 2, 4, 11 months; Yes
Pneumo_ps Yes adults at risk
YF 12 months, No French Guyana
Zoster 65-74 years;

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  No  No  No  No  No  No 
What years does the MYP cover? number 2012-2017             
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 101  101  101  101  101  101  100 
Nº districts with DTP3 coverage >=80% number         89     
% of districts with DTP3 coverage >=80% From 0 to 100%         88     
Nº districts with measles (MCV1) coverage >=95% number            
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  No  No    Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.